Project: A novel topical therapy for Atopic Dermatitis through development of LXR agonists
This project will deliver a novel topical therapy for Atopic Dermatitis (AD). AD is a common, chronic, inflammatory skin disease. A great body of evidence supports Liver X Receptors (LXRs) as a therapeutic target for AD. The DERMAL project will perform lead selection and preclinical development based on a newly identified chemical series of LXR agonists. This project will produce formulated lead compounds that will be ready for clinical trials within 18 months after completion of this project.
| Acronym | DERMAL (Reference Number: 10449) |
| Duration | 01/10/2016 - 01/10/2019 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 5 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 24104 | Lead Pharma Holding BV | Coordinator | Netherlands |
| 24105 | Saretius Ltd. | Partner | United Kingdom |
| 24106 | StratiCELL SA/NV | Partner | Belgium |
| 24107 | BioAdvice AS | Partner | Denmark |
| 24108 | SiSaf Ltd. | Partner | United Kingdom |